**1. Financial Highlights:** AHCL's Q1 FY26 saw Net Sales up 12.31% to ₹94.05 Cr.

PBT surged 77.80% to ₹11.29 Cr, PAT jumped 79.87% to ₹8.31 Cr.

Pain Management grew 26%, Comfy 11%. Rehydration sales declined 17%. Management aims for 13% operating profit margin (from 11.44%). **2. Strategic Initiatives & Growth Drivers:** Focus on boosting Amrutanjan balm household penetration via consumer engagement.

Expanding sales/distribution networks, including Pharma Super Stockists, is active.

Operational efficiency and Ecom/Quick Commerce channel growth are core priorities. **3. Business Developments:** Strong product performance observed in Pain Management and Congestion lines.

Comfy's XL variant and value packs also boosted Women's Hygiene.

Sales infrastructure improved with increased stockist network and productivity gains. **4. Market Position & Competitive Advantage:** Amrutanjan's Pain Management volume growth significantly outpaced competitors.

It holds a leading share in the growing Roll-on category, validated by new market entrants. **5. Investor Implications:** The quarter shows positive growth potential, driven by robust Pain Management and strategic market expansion.

Key watch areas: margin expansion and Rehydration segment recovery.